Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clearmind Medicine Inc. Logo
Clinical-stage psychedelic pharma firm developing treatments for Alcohol Use Disorder.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Biopharmaceutical firm with an FDA-approved microinjector for back-of-the-eye delivery.
United States of America
CLSD
Clene Inc. Logo
A clinical-stage biopharma developing nanotherapeutics for neurodegenerative diseases.
United States of America
CLNN
CMG Pharmaceutical Co., Ltd. Logo
A pharmaceutical firm specializing in Oral Thin Film drug delivery technology.
South Korea
058820
CNS Pharmaceuticals, Inc. Logo
Develops anti-cancer drug candidates for cancers of the brain and nervous system.
United States of America
CNSP
Cocrystal Pharma, Inc. Logo
Clinical-stage biotech developing antiviral drugs for serious and chronic viral diseases.
United States of America
COCP
Co-Diagnostics, Inc. Logo
A molecular diagnostics company that develops and markets advanced PCR technologies.
United States of America
CODX
co.don AG Logo
Develops autologous cell therapies for regenerative treatment of cartilage defects.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Biopharmaceutical company developing cell therapy platforms for cancer and other diseases.
United States of America
COEP
Cogent Biosciences, Inc. Logo
A clinical-stage biotech company developing precision therapies for genetic diseases.
United States of America
COGT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.